EBS Reports That Its NEXT WAVE(TM) Brain Stimulation Device Expanded the Visual Field by a Mean Average of 24% in a Clinical Study of 82 Patients with Impaired Vision Caused by Optic Nerve Neuropathy or Stroke

Contact if interested.
http://online.wsj.com/article/PR-CO-20130604-905592.html?mod=googlenews_wsj
EBS Technologies GmbH, an emerging medical device company developing the revolutionary NEXT WAVE(TM) brain stimulation platform for treatment of vision deficits caused by neurological disorders, announced today the results of a multi-center, 82-patient clinical trial of its NEXT WAVE(TM) brain stimulation device.
About one-half of the clinical trial patients were given a 40-minute treatment protocol for 10 consecutive days with the NEXT WAVE(TM) device. With a mean increase of 24%, NEXT WAVE(TM)-treated patients showed significantly better improvements in stimulation of their total visual field compared to patients in the control group, which did not receive NEXT WAVE(TM) stimulation. All patients had vision impairment lasting at least six months prior to the clinical trial and had exhausted all standard therapeutic options to improve their vision.
"There is a huge unmet clinical need for the treatment of vision impairment caused by a variety of different neurological disorders, such as neuropathy of the optic nerve, brain injury or stroke. For example, stroke alone is the world's third-leading cause of death as well as the leading cause of serious, long-term disability. There are more than 10.4 million stroke survivors with long-term disability in Europe and the U.S. Three out of five of these disabled persons are potentially treatable with our NEXT WAVE(TM) therapy once we commence commercialization," said Ulf Pommerening, CEO of EBS Technologies.
"We look forward to expanding the scientific evidence for the efficacy of our NEXT WAVE(TM) approach, especially in stroke patients, in an expanded clinical trial that will commence imminently," said Pommerening.